Physician profile
Jeffrey Vanwingen
NPI 1053349993
$11,844.19
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $8,641 · 2021: $1,134 · 2022: $432 · 2023: $813 · 2024: $21.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,202.40 | 2020-2021 | |
| Novo Nordisk INC | $496.98 | 2019-2023 | Ozempic, Rybelsus, Saxenda |
| Merz North America, INC. | $437.25 | 2023 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $316.85 | 2019-2023 | Farxiga |
| Pfizer INC. | $204.87 | 2019-2020 | |
| Abbvie INC. | $186.64 | 2020-2023 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $155.45 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $108.97 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $104.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.90 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $76.33 | 2021-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $56.39 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $55.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $52.45 | 2019-2023 | Vaxelis, Vaxneuvance, Rotateq |
| Almatica Pharma LLC | $39.76 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.08 | 2020-2023 | Jardiance |
| Currax Pharmaceuticals LLC | $31.20 | 2022-2023 | Contrave, Onzetra Xsail |
| Sanofi-Aventis U.S. LLC | $29.36 | 2019-2021 | |
| Astellas Pharma US INC | $29.01 | 2019-2021 | |
| Exact Sciences Corporation | $23.01 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $20.87 | 2023 | Sunosi |
| Jazz Pharmaceuticals INC. | $19.17 | 2021 | |
| Philips North America LLC | $18.24 | 2021 | |
| Shire North American Group INC | $14.90 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.91 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.79 | 2022 | |
| Cranial Technologies, INC | $11.63 | 2022 | |
| Athena Bioscience, LLC | $6.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Vanwingen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.